ArticleBlood2009
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.British journal of cancer · 2024Article
- Chemokine CCL6 Plays Key Role in the Inhibitory Effect of Vitamin A on Norovirus Infection.Journal of microbiology (Seoul, Korea) · 2023Article
- Mouse CCL9 Chemokine Acts as Tumor Suppressor in a Murine Model of Colon Cancer.Current issues in molecular biology · 2023Article
- TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells.International journal of oncology · 2022Article
- Sublytic C5b-9 Induces CCL3/4 Production and Macrophage Accumulation in Thy-1N Rats via PKC-α/p65/IRF-8 Axis.International journal of biological sciences · 2022Article
- Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.Cancer immunology research · 2021Article
- IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells.Cancers · 2021Article
- CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Identification of a Hematopoietic Cell Population Emerging From Mouse Bone Marrow With Proliferative PotentialFrontiers in immunology · 2021Article
- Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.Leukemia · 2020Article
- Upregulation of Immune Process-Associated Genes in RAW264.7 Macrophage Cells in Response toBioMed research international · 2018Article
- Regulation of myelopoiesis by the transcription factor IRF8.International journal of hematology · 2015Review
- Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.Leukemia · 2015Article
- Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.PloS one · 2014Article
- Batf3 and Id2 have a synergistic effect on Irf8-directed classical CD8α+ dendritic cell development.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.The Journal of experimental medicine · 2013Article
- Article
- Mammary gland morphological and gene expression changes underlying pregnancy protection of breast cancer tumorigenesis.Physiological genomics · 2012Article
- Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.BMC cancer · 2011Article
- IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.Cancer research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Interferon (IFN) is effective at inducing complete remissions in patients with chronic myelogenous leukemia (CML), and evidence supports an immune mechanism. Here we show that the type I IFNs (alpha and beta) regulate expression of the IFN consensus sequence-binding protein (ICSBP) in BCR-ABL-transformed cells and as shown previously for ICSBP, induce a vaccine-like immunoprotective effect in a murine model of BCR-ABL-induced leukemia. We identify the chemokines CCL6 and CCL9 as genes prominently induced by the type I IFNs and ICSBP, and demonstrate that these immunomodulators are required for the immunoprotective effect of ICSBP expression. Insights into the role of these chemokines in the antileukemic response of IFNs suggest new strategies for immunotherapy of CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.